ERBB2 and neoplasm: The study testified that the anti-HER2 nanobody showed high, specific tumor uptake but low kidney uptake, demonstrating that anti-HER2 nanobodies have good sensitivity for tumor detection with non-toxicity in a preclinical, validated therapy [101].